Pharmacogenetics of breast cancer therapies (Q37633176)

21 August 2017

1 reference

title

Pharmacogenetics of breast cancer therapies (English)

1 reference

21 August 2017

Daniel L Hertz

1

1 reference

21 August 2017

Howard L McLeod

series ordinal

2

1 reference

21 August 2017

Janelle M Hoskins

series ordinal

3

1 reference

21 August 2017

publication date

1 October 2009

1 reference

21 August 2017

1 reference

21 August 2017

volume

18 Suppl 3

1 reference

21 August 2017

page(s)

S59-63

1 reference

Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

Aggressive adriamycin-containing regimen (PM-FAC) in estrogen receptor-negative disseminated breast cancer. Results of a Southwest Oncology Group trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

HER2 as a prognostic factor in breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

Development of the 21-gene assay and its application in clinical practice and clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

A "silent" polymorphism in the MDR1 gene changes substrate specificity

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

Cytotoxicity mediated by human Fc receptors for IgG.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

The efficacy of rituximab plus Hyper-CVAD regimen in mantle cell lymphoma is independent of FCgammaRIIIa and FCgammaRIIa polymorphisms

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

Dose-response relationship and pharmacogenetics of anti-RhD monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

Guidelines for the adjuvant treatment of postmenopausal women with endocrine-responsive breast cancer: past, present and future recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970275-9

7 January 2021

10.1016/S0960-9776(09)70275-9

Identifiers

DOI

1 reference

21 August 2017

1 reference